Ratings Moves: MGM,...
Health Care: Health Services
Navidea Biopharmaceuticals Inc (NAVB: AMEX)
$2.43 0.03 | 1.25%
05/23/13 - 02:06 PM ET
318.79K / 1.41M
Vol / Avg. Vol:2.38 / 2.40
Open / Prev. Close:2.36 - 2.45
Today's Range:2.14 - 4.77
52 Wk Range:-11.66%
Performance YTD:TheStreet Rating:
Portfolios with NAVB
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserMy stocks
- ContributorDrugs Facing FDA Approval i...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- Userjennydog
- UserRogers BioMed
Latest NAVB Headlines from TheStreet
- 6 Stocks Under $10 Spiking Higher 04.04.13 | 03:04 pm
- Biotech Stock Mailbag: Delcath, Navidea, Affymax, Ziopharm 03.15.13 | 06:03 am
- Best And Worst FDA Drug Approval Stocks of 2013 03.12.13 | 08:03 am
- Play TheStreet's FDA Drug Approval Contest 03.05.13 | 12:03 pm
- Biotech Stock Mailbag: Celsion, Navidea, AP Pharma, Sarepta 02.01.13 | 07:02 am
- 5 Biotech Stocks Under $10 Moving Higher 01.30.13 | 08:01 am
- The Twitterverse's Biotech Stock Picks for 2013 01.02.13 | 08:01 am
- 13 Biotech Stock Predictions for 2013 01.02.13 | 06:01 am
- 2013 FDA Drug Approval Decision Calendar 12.19.12 | 09:12 am
- MAP Pharma's Awkward FDA Silence 11.14.12 | 09:11 am
Press Releases for NAVB
- Navidea Biopharmaceuticals Announces Enrollment Of First Subject In Phase 2b Trial Of NAV4694 In Subjects With Mild Cognitive Impairment (MCI) - Business Wire 03.27.13 | 09:03 am
- Results Of Lymphoseek® Phase 3 Clinical Trials In Breast Cancer Published In Annals Of Surgical Oncology - Business Wire 03.21.13 | 09:03 am
- Navidea Biopharmaceuticals To Hold Conference Call To Discuss Lymphoseek FDA Approval - Business Wire 03.13.13 | 02:03 pm
- FDA Approves Navidea’s Lymphoseek® (technetium Tc 99m Tilmanocept) Injection For Use In Lymphatic Mapping - Business Wire 03.13.13 | 01:03 pm
- Navidea Announces Fourth Quarter And Full-Year 2012 Results - Business Wire 03.06.13 | 04:03 pm
- Navidea Biopharmaceuticals To Announce Fourth-Quarter And Full-Year 2012 Financial Results On Wednesday, March 6, 2013 - Business Wire 03.04.13 | 02:03 pm
- Navidea Biopharmaceuticals To Present At The Cowen & Company 33rd Annual Health Care Conference - Business Wire 02.28.13 | 09:02 am
- Navidea Biopharmaceuticals To Present At The Citi 2013 Global Healthcare Conference - Business Wire 02.19.13 | 08:02 am
- Navidea Biopharmaceuticals Announces The Presentation Of Lymphoseek® Data At Upcoming Scientific Meetings - Business Wire 02.07.13 | 08:02 am
- Navidea Biopharmaceuticals To Present At The 15th Annual BIO CEO & Investor Conference - Business Wire 02.06.13 | 10:02 am
Partner Headlines for NAVB
- A Likely Turnaround And Short Squeeze For Navidea Shares - Seeking Alpha 03.18.13 | 09:03 am
- Quality Investors Knock On Navidea's Door; Validates Lymphoseek Potential - Seeking Alpha 01.31.13 | 09:01 am
- Navidea's Catalyst Will Pay Off - Seeking Alpha 01.16.13 | 09:01 am
- Testing, Testing: Analyst Kevin DeGeeter On 5 Good Bets In Cancer Diagnostics - Seeking Alpha 11.30.12 | 09:11 am
- Navidea: Interesting Biotech Story Gets Even More Dramatic - Seeking Alpha 10.02.12 | 09:10 am
- Morning Market Losers - Benzinga 09.11.12 | 09:09 am
- 4 Highly Liquid Small Cap Healthcare Stocks Set For Growth - Seeking Alpha 09.04.12 | 09:09 am
